The dilemma of a rising prostate-specific antigen level after local therapy: What are our options?

Nicholas G. Zaorsky, Ganesh V. Raj, Edouard J. Trabulsi, Jianqing Lin, Robert B. Den

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Prostate cancer is the most common solid tumor diagnosed in men in the United States and Western Europe. Primary treatment with radiation or surgery is largely successful at controlling localized disease. However, a significant number (up to one third of men) may develop biochemical recurrence (BR), defined as a rise in serum prostate-specific antigen (PSA) level. A general presumption is that BR will lead to overt progression in patients over subsequent years. There are a number of factors that a physician must consider when counseling and recommending treatment to a patient with a rising PSA. These include the following (1) various PSA-based definitions of BR; (2) source of PSA (ie, local or distant disease, residual benign prostate); (3) available modalities to treat the disease with the least morbidity; and (4) timing of therapy. In this article we review the current and future factors that clinicians should consider in the diagnosis and treatment of recurrent prostate cancer.

Original languageEnglish (US)
Pages (from-to)322-336
Number of pages15
JournalSeminars in Oncology
Volume40
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Prostate-Specific Antigen
Recurrence
Prostatic Neoplasms
Therapeutics
Counseling
Prostate
Radiation
Morbidity
Physicians
Serum
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

The dilemma of a rising prostate-specific antigen level after local therapy : What are our options? / Zaorsky, Nicholas G.; Raj, Ganesh V.; Trabulsi, Edouard J.; Lin, Jianqing; Den, Robert B.

In: Seminars in Oncology, Vol. 40, No. 3, 06.2013, p. 322-336.

Research output: Contribution to journalArticle

Zaorsky, Nicholas G. ; Raj, Ganesh V. ; Trabulsi, Edouard J. ; Lin, Jianqing ; Den, Robert B. / The dilemma of a rising prostate-specific antigen level after local therapy : What are our options?. In: Seminars in Oncology. 2013 ; Vol. 40, No. 3. pp. 322-336.
@article{e127f7c53c5b445d8237de0a384cdc16,
title = "The dilemma of a rising prostate-specific antigen level after local therapy: What are our options?",
abstract = "Prostate cancer is the most common solid tumor diagnosed in men in the United States and Western Europe. Primary treatment with radiation or surgery is largely successful at controlling localized disease. However, a significant number (up to one third of men) may develop biochemical recurrence (BR), defined as a rise in serum prostate-specific antigen (PSA) level. A general presumption is that BR will lead to overt progression in patients over subsequent years. There are a number of factors that a physician must consider when counseling and recommending treatment to a patient with a rising PSA. These include the following (1) various PSA-based definitions of BR; (2) source of PSA (ie, local or distant disease, residual benign prostate); (3) available modalities to treat the disease with the least morbidity; and (4) timing of therapy. In this article we review the current and future factors that clinicians should consider in the diagnosis and treatment of recurrent prostate cancer.",
author = "Zaorsky, {Nicholas G.} and Raj, {Ganesh V.} and Trabulsi, {Edouard J.} and Jianqing Lin and Den, {Robert B.}",
year = "2013",
month = "6",
doi = "10.1053/j.seminoncol.2013.04.011",
language = "English (US)",
volume = "40",
pages = "322--336",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - The dilemma of a rising prostate-specific antigen level after local therapy

T2 - What are our options?

AU - Zaorsky, Nicholas G.

AU - Raj, Ganesh V.

AU - Trabulsi, Edouard J.

AU - Lin, Jianqing

AU - Den, Robert B.

PY - 2013/6

Y1 - 2013/6

N2 - Prostate cancer is the most common solid tumor diagnosed in men in the United States and Western Europe. Primary treatment with radiation or surgery is largely successful at controlling localized disease. However, a significant number (up to one third of men) may develop biochemical recurrence (BR), defined as a rise in serum prostate-specific antigen (PSA) level. A general presumption is that BR will lead to overt progression in patients over subsequent years. There are a number of factors that a physician must consider when counseling and recommending treatment to a patient with a rising PSA. These include the following (1) various PSA-based definitions of BR; (2) source of PSA (ie, local or distant disease, residual benign prostate); (3) available modalities to treat the disease with the least morbidity; and (4) timing of therapy. In this article we review the current and future factors that clinicians should consider in the diagnosis and treatment of recurrent prostate cancer.

AB - Prostate cancer is the most common solid tumor diagnosed in men in the United States and Western Europe. Primary treatment with radiation or surgery is largely successful at controlling localized disease. However, a significant number (up to one third of men) may develop biochemical recurrence (BR), defined as a rise in serum prostate-specific antigen (PSA) level. A general presumption is that BR will lead to overt progression in patients over subsequent years. There are a number of factors that a physician must consider when counseling and recommending treatment to a patient with a rising PSA. These include the following (1) various PSA-based definitions of BR; (2) source of PSA (ie, local or distant disease, residual benign prostate); (3) available modalities to treat the disease with the least morbidity; and (4) timing of therapy. In this article we review the current and future factors that clinicians should consider in the diagnosis and treatment of recurrent prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84879455949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879455949&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2013.04.011

DO - 10.1053/j.seminoncol.2013.04.011

M3 - Article

C2 - 23806497

AN - SCOPUS:84879455949

VL - 40

SP - 322

EP - 336

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3

ER -